-+ 0.00%
-+ 0.00%
-+ 0.00%

BMO Capital Maintains Outperform on Terns Pharma, Raises Price Target to $54

Benzinga·12/09/2025 16:52:54
Listen to the news
BMO Capital analyst Evan Seigerman maintains Terns Pharma (NASDAQ:TERN) with a Outperform and raises the price target from $35 to $54.